Aimmune Therapeutics–JPMorgan Chase: investor conference, 201801 supply service Aimmune presents at JP Morgan Healthcare Conference 2018

	Period	2018-01-10
	Region	San Francisco, CA
	Country	United States (USA)
	Partner, 1st	Aimmune Therapeutics Inc. (Nasdaq: AIMT)
	Group	Nestlé (Group)
	Partner, 2nd	J.P. Morgan Securities LLC
	Group	JPMorgan Chase (Group)
	Product	J.P. Morgan 36th Annual Healthcare Conference 2018 San Francisco
	Product 2	CODIT™ (Characterized Oral Desensitization ImmunoTherapy)
	Person	Dilly, Stephen (Sierra Oncology 202204 CEO formerly Aimmune Therapeutics 201611–201806 CEO + Chiron BioPharma)
	Person 2	Hansen, Laura (Aimmune Therapeutics 201801 Investor Relations)

Aimmune Therapeutics, Inc.. (1/3/18). "Press Release: Aimmune Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference". Brisbane, CA.

— Presentation on Wednesday, January 10, 2018, at 7:30 a.m. Pacific Time —

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will present a company overview at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2018, at 7:30 a.m. Pacific Time. A breakout session will immediately follow the presentation.

A live audio webcast of the presentation and breakout session will be accessible from the Investor Relations section of the Aimmune website at www.aimmune.com. A replay of the webcast will be available at www.aimmune.com for at least 30 days following the webcast.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials. For more information, please see www.aimmune.com.

This press release concerns a product that is under clinical investigation and that has not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It is currently limited to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.

Aimmune Therapeutics, Inc.

Investors
Laura Hansen, Ph.D., 650-396-3814
lhansen@aimmune.com
or
Media
Stephanie Yao, 650-351-6479
syao@aimmune.com